Dr Sally Martin
Dr Martin is currently a post-doctoral researcher in the Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, based at the SAHMRI, Cancer Theme.
Dr Martin's PhD research, completed in 2009, centred on bone marrow angiogenesis and osteolytic bone disease in the haematological malignancy, multiple myeloma. Since completing her PhD studies, Dr Martin has been examining the role of the PI3K and mTOR signalling pathways in bone development, looking at ways to exploit these pathways to stimulate bone formation in disease settings such as osteoporosis and tumour-associated bone loss.
Dr Martin is an affiliate lecturer in the School of Medical Sciences and the School of Medicine, University of Adelaide.
Dr Martin's current research projects are focussed on (1) the role of the mTOR signalling pathways in mesenchymal stem cell biology, (2) the role of the mTOR signalling pathways in regulating skeletal biology and bone remodelling, and (3) the role of skeletal mTORC1 signalling in B-cell development and glucose homeostasis.
|2015||Post-doctoral Researcher||University of Adelaide, Adelaide|
|2013||Affiliate Lecturer||University of Adelaide|
|2012||Affiliate Lecturer||University of Adelaide|
|2009 - 2015||Post-doctoral Researcher||SA Pathology|
|2003 - 2008||Technical Assistant (part-time)||Institute of Medical and Veterinary Science (IMVS)|
|2005 - 2008||University of Adelaide, Adelaide||Australia||PhD|
|2000 - 2004||University of South Australia||Australia||Bachelor of Medical and Pharmaceutical Biotechnology (Hons)|
|2017||Fitter,S, Matthews,M, Martin,S, Xie,J, Ooi,S, Walkley,C, Codrington,J, Ruegg,M, Hall,M, Proud,C et al, 2017, mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation, Molecular and Cellular Biology, 37, 7, e00668-1-e00668-20 10.1128/MCB.00668-16|
|2015||Cheong,C, Chow,A, Fitter,S, Hewett,D, Martin,S, Williams,S, To,L, Zannettino,A, Vandyke,K, 2015, Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo, Experimental Cell Research, 332, 1, 24-38 10.1016/j.yexcr.2015.01.006|
|2015||Martin,S, Gan,Z, Fitter,S, To,L, Zannettino,A, 2015, The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma, Leukemia Research, 39, 3, 380-387 10.1016/j.leukres.2014.12.015|
|2015||Forristal,C, Brown,A, Helwani,F, Winkler,I, Nowlan,B, Barbier,V, Powell,R, Engler,G, Diakiw,S, Zannettino,A et al, 2015, Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML, Leukemia, 29, 10, 2075-2085 10.1038/leu.2015.102|
|2015||Martin,S, Fitter,S, Dutta,A, Matthews,M, Walkley,C, Hall,M, Ruegg,M, Gronthos,S, Zannettino,A, 2015, Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation, Stem Cells, 33, 4, 1359-1365 10.1002/stem.1931|
|2015||Gan,Z, Fitter,S, Vandyke,K, To,L, Zannettino,A, Martin,S, 2015, The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma, European Journal of Haematology, 94, 4, 343-354 10.1111/ejh.12436|
|2011||Martin,S, Diamond,P, Gronthos,S, Peet,D, Zannettino,A, 2011, The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma, Leukemia, 25, 10, 1533-1542 10.1038/leu.2011.122|
|2010||Martin,S, Fitter,S, Bong,L, Drew,J, Gronthos,S, Shepherd,P, Zannettino,A, 2010, NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells, Journal of Bone and Mineral Research, 25, 10, 2126-2137 10.1002/jbmr.114|
|2010||Williams,S, Martin,S, Vincent,C, Gronthos,S, Zheng,T, Atkins,G, Zannettino,A, 2010, Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients, British Journal of Haematology, 150, 3, 373-376 10.1111/j.1365-2141.2010.08201.x|
|2010||Martin,S, Diamond,P, Williams,S, To,L, Peet,D, Fujii,N, Gronthos,S, Harris,A, Zannettino,A, 2010, Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells, Haematologica, 95, 5, 776-784 10.3324/haematol.2009.015628|
|2010||Psaltis,P, Paton,S, See,F, Arthur,A, Martin,S, Itescu,S, Worthley,S, Gronthos,S, Zannettino,A, 2010, Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations, Journal of Cellular Physiology, 223, 2, 530-540 10.1002/jcp.22081|
|2009||Labrinidis,A, Diamond,P, Martin,S, Hay,S, Liapis,V, Zinonos,I, Sims,N, Atkins,G, Vincent,C, Ponomarev,V et al, 2009, Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma, Clinical Cancer Research, 15, 6, 1998-2009 10.1158/1078-0432.CCR-08-2444|
|2009||Diamond,P, Labrinidis,A, Martin,S, Farrugia,A, Gronthos,S, To,L, Fujii,N, O'Loughlin,P, Evdokiou,A, Zannettino,A et al, 2009, Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss, Journal of Bone and Mineral Research, 24, 7, 1150-1161 10.1359/JBMR.090210|
|2006||Martin,S, Dewar,A, Farrugia,A, Horvath,N, Gronthos,S, To,L, Zannettino,A, 2006, Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma, Clinical Cancer Research, 12, 23, 6973-6977 10.1158/1078-0432.CCR-06-0323|
|2005||Zannettino,A, Farrugia,A, Kortesidis,A, Manavis,J, To,L, Martin,S, Diamond,P, Tamamura,H, Lapidot,T, Fujii,N et al, 2005, Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients, Cancer Research, 65, 5, 1700-1709 10.1158/0008-5472.CAN-04-1687|
|2004||Martin,S, To,L, Horvath,N, Zannettino,A, 2004, Angiogenesis in multiple myeloma: Implications in myeloma therapy, Cancer Reviews: Asia-Pacific, 2, 2, 119-129 10.1142/S0219836304000470|
Mary Overton Early Career Research Fellowship (2012 - 2015), The role of the raptor and rictor signalling pathways in skeletal biology, AUD$252,000
Centre for Stem Cell Research Project Grant 2012, The role of raptor and rictor in MSC differentiation, AUD$75,000
Novartis Pharmaceuticals Project Grant 2011, Can the dual PI3K/mTOR inhibitor NVP-BEZ235 be used to stimulate bone formation in multiple myeloma? AUD$75,000.
2015-present: Ms Pawanrat Tangseefa, PhD scholar
2013: Mr Ankit Dutta, Honours scholar
2010-2017: Ms Mary Matthews, PhD scholar
2009-2014: Ms Catherine Gan, Masters scholar